Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Operating Leases (2022 - 2025)

Altimmune (ALT) has disclosed Operating Leases for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 18.33% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 18.33% year-over-year, with the annual reading at $1.1 million for FY2025, 18.33% down from the prior year.
  • Operating Leases for Q4 2025 was $1.1 million at Altimmune, down from $1.2 million in the prior quarter.
  • The five-year high for Operating Leases was $1.5 million in Q2 2024, with the low at $44000.0 in Q1 2024.
  • Average Operating Leases over 4 years is $1.0 million, with a median of $1.2 million recorded in 2025.
  • The sharpest move saw Operating Leases plummeted 73.96% in 2023, then surged 2950.0% in 2025.
  • Over 4 years, Operating Leases stood at $672000.0 in 2022, then tumbled by 73.96% to $175000.0 in 2023, then surged by 701.14% to $1.4 million in 2024, then decreased by 18.33% to $1.1 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $1.1 million, $1.2 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.